Merck and Pfizer’s Steglatro meets primary goal in VERTIS CV trial
Merck (MSD) and Pfizer have reported that the Phase III VERTIS cardiovascular (CV) outcomes clinical trial of Steglatro (ertugliflozin) met its primary endpoint in patients with type 2 diabetes and atherosclerotic CV disease.
Lilly begins dosing in cardiovascular outcomes trial of tirzepatide
Eli Lilly has dosed the first participants in the Phase III SURPASS-CVOT cardiovascular outcomes trial of tirzepatide in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Boehringer and Lilly study Jardiance in EMPACT-MI heart failure trial
Boehringer Ingelheim and Eli Lilly have partnered with the Duke Clinical Research Institute (DCRI) to conduct an EMPACT-MI clinical trial of Jardiance (empagliflozin) to prevent heart failure.
AstraZeneca to stop DAPA-CKD trial of Farxiga early
AstraZeneca is set to stop the Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) early after the drug showed encouraging efficacy profile.
Neurimmune enrols patient in NI006 trial for ATTR cadiomyopathy
Zurich-based biopharmaceutical firm Neurimmune has enrolled the first patient in a Phase I clinical trial to analyse NI006 in transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy).
Recardio to continue Phase II trial of dutogliptin
Life science company Recardio is set to continue the Phase II clinical trial of its dutogliptin drug in combination with filgrastim in severe heart attack patients.
Boehringer Ingelheim reports positive CV data of linagliptin
Boehringer Ingelheim has reported positive data from a subgroup analysis of the CARMELINA clinical trial of linagliptin in type 2 diabetes patients.
Novartis plans inclisiran’s primary prevention study in UK
Novartis is planning to conduct a primary prevention study of inclisiran, a cholesterol-lowering drug, with the UK as the global trial centre.
AskBio initiates Phase I trial of gene therapy for heart failure
Asklepios BioPharmaceutical (AskBio) and its subsidiary NanoCor Therapeutics have dosed the first patient in a Phase I clinical trial of gene therapy candidate NAN-101 to treat congestive heart failure.